Because changes in the expression of NKG2D ligands (such as MICA/B) on tumor cells can modify the recognition and activation of NK cells via NKG2D, while the previous result showed that TM reduced MICA/B levels, we next tested whether treatment of HCC cells with TM could also lead to decreased activation and NK cell-mediated killing. This evidence concerns the gene MICA and hepatocellular carcinoma.